Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis.
A double-blind group comparative trial comparing Opticrom with a matching placebo, over a four-week period, in seasonal allergic conjunctivitis is reported. Overall assessment of treatment benefit made at the end of the trial by the patients and the clinician showed a statistically significant difference in favour of Opticrom. Of the patients on Opticrom, eighteen (90%) said they improved while in the clinicians opinion, seventeen (85%) improved. Six patients using Opticrom and five using placebo complained of stinging of the eyes, while one patient using placebo complained of his eyes becoming bloodshot and watering.
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000627:therapeutic use; D011058:Pollen; D012621:Seasons
D010919:Placebos; D004205:Cromolyn Sodium